Drug Profile
Tenapanor - Ardelyx
Alternative Names: AZD-1722; AZD1722-hydrochloride; IBSRELA; Ibsrela; KHK-7791; PHOZEVEL; RDX-5791; Tenapanor hydrochloride; XPHOZAHLatest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator Ardelyx
- Developer Ardelyx; Knight Therapeutics; Kyowa Kirin; Shanghai Fosun Pharmaceutical
- Class Benzylisoquinolines; Chlorinated hydrocarbons; Gastrokinetics; Heart failure therapies; Hyperphosphataemia therapies; Irritable bowel syndrome therapies; Small molecules; Sulfonamides; Urea compounds; Urologics
- Mechanism of Action Sodium-hydrogen exchanger 3 inhibitors; TRPV1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperphosphataemia; Irritable bowel syndrome
- Phase II Renal failure
- Discontinued Heart failure
Most Recent Events
- 20 Feb 2024 Kyowa Kirin plans to launch Tenapanor (PHOZEVEL® ) for Hyperphosphataemia in Japan (PO)
- 27 Nov 2023 Ardelyx initiates a phase I pharmacokinetic trial (In volunteers) in USA (PO) (NCT06203444)
- 15 Nov 2023 Tenapanor - Ardelyx receives Orphan Drug status for Pediatric Hyperphosphataemia in USA